Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase
Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase
合成生物製品公司宣佈前6名參與者服用SYN-020腸道鹼性磷酸酶1a期臨牀試驗
Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced that enrollment has commenced and six study participants were dosed in a Phase 1a single-ascending dose clinical trial of SYN-020 intestinal alkaline phosphatase ("IAP").
合成生物製品公司(紐約證券交易所：同步)，一家利用微生物羣開發治療藥物的多元化臨牀階段公司，旨在預防和治療高需求地區的胃腸道(GI)疾病，該公司今天宣佈，已開始招募，6名研究參與者參加了SYN-020腸道鹼性磷酸酶(“IAP”)的第1階段單劑量遞增臨牀試驗。